Grant of Interim Extension of the Term of U.S. Patent No. 4,585,770; ZILMAX® (Zilpaterol Hydrochloride), 16765 [E6-4831]
Download as PDF
<![CDATA[
sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 71, No. 64 / Tuesday, April 4, 2006 / Notices
alternatives to allocate halibut between
the charter and commercial sectors. One
alternative would be a percentage
allocation to the charter sector.
Elements to be considered include, but
are not limited to: (1) A percentage
based allocation that would float up and
down with halibut abundance; (2)
Subdivision of Area 2C and 3A into
smaller geographic sub-districts; (3)
Management measures that will be used
to enforce the allocation, including: (a)
the current suite of measures to reduce
harvests under the Guideline Harvest
Level (GHL) (i.e., one trip per vessel per
day, no harvest by skipper and crew,
and annual limit of 5 or 6 fish per
person (for Area 2C only); (b) Limits on
the number of lines fished to the
number of clients; (c) Other annual bag
limits; (d) Limits on days fished (either
total number of days or by excluding
specific days of the week); (e) Reduced
daily limits including size limitations
for the second fish caught; (f)
Subtraction of any allocation overage
from the following year’s allocation; (g)
Federal limited entry program with
delayed transferability; (h) Mechanisms
which, if the charter harvest continues
to grow, would allow for an orderly and
compensated allocation shift from the
longline sector to the charter sector,
including the use of a charter stamp or
other funding mechanisms to generate
funds to buy commercial quota shares to
convert commercial allocation to the
charter sector and to pay for
management of the charter fishery.
A second alternative would be an
Individual Fishing Quota (IFQ) program,
including, but not be limited to: (1)
Elements of the previously proposed
(2001) charter IFQ program; (2) A
modified IFQ program, including, but
not be limited to, including recent
participants who were not included in
the 2001 plan. Such approaches might
include a ‘‘leveling’’ plan, other effort
based mechanisms to update 1998 and
1999 history, new history approaches,
an effort based transferable seat
program, or other options; (3)
Subdivision of Area 2C and 3A into
smaller geographic sub-districts; and (4)
Other elements to be identified by the
committee.
Although non-emergency issues not
contained in this agenda may come
before this group for discussion, those
issues may not be the subject of formal
action during this meeting. Action will
be restricted to those issues specifically
identified in this notice and any issues
arising after publication of this notice
that require emergency action under
section 305(c) of the Magnuson-Stevens
Fishery Conservation and Management
Act, provided the public has been
VerDate Aug<31>2005
18:55 Apr 03, 2006
Jkt 208001
notified of the Council’s intent to take
final action to address the emergency.
Special Accommodations
These meetings are physically
accessible to people with disabilities.
Requests for sign language
interpretation or other auxiliary aids
should be directed to Gail Bendixen at
(907) 271–2809 at least 7 working days
prior to the meeting date.
Dated: March 30, 2006
Tracey L. Thompson,
Acting Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
[FR Doc. E6–4802 Filed 4–3–06; 8:45 am]
BILLING CODE 3510–22–S
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2006–0020]
Grant of Interim Extension of the Term
of U.S. Patent No. 4,585,770; ZILMAX
(Zilpaterol Hydrochloride)
United States Patent and
Trademark Office, DOC.
ACTION: Notice of interim patent term
extension.
AGENCY:
SUMMARY: The United States Patent and
Trademark Office has issued certificates
under 35 U.S.C. 156(d)(5) for three oneyear interim extensions of the term of
U.S. Patent No. 4,585,770.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Patent Ext., P.O. Box
1450, Alexandria, VA 22313–1450; by
fax marked to her attention at (571) 273–
7755, or by e-mail to
Mary.Till@uspto.gov.
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On March 26, 2003, patent owner,
Hoechst Roussel Vet S.A., timely filed
an application under 35 U.S.C. 156(d)(5)
for an interim extension of the term of
U.S. Patent No. 4,585,770. On March 31,
2004, patent owner, Hoechst Roussel
Vet S.A., timely filed a second
application under 35 U.S.C. 156(d)(5)
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00010
Fmt 4703
Sfmt 4703
16765
for a second interim extension of the
term of U.S. Patent No. 4,585,770. On
March 29, 2005, patent owner, Hoechst
Roussel Vet S.A., timely filed a third
application under 35 U.S.C. 156(d)(5)
for a third interim extension of the term
of U.S. Patent No. 4,585,770. The patent
claims the active ingredient, zilpaterol
hydrochloride, in the animal drug
product Zilmax. The application
indicates that an Investigational New
Animal Drug Application for the animal
drug product, Zilmax (zilpaterol
hydrochloride), has been filed and is
currently undergoing regulatory review
before the Food and Drug
Administration for permission to market
or use the product commercially.
Review of the application indicates
that, except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for one year as required by
35 U.S.C. 156(d)(5)(B). Since it is
apparent that the regulatory review
period has continued beyond the
original expiration date of the patent
(October 12, 2003), interim extension of
the patent term under 35 U.S.C.
156(d)(5) is appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
4,585,770, is granted for a period of one
year from the original expiration date of
the patent, i.e., until October 12, 2004;
a second interim extension under 35
U.S.C. 156(d)(5) of the term of U.S.
Patent No. 4,585,770, is granted for an
additional period of one year from the
extended expiration date of the patent,
i.e., until October 12, 2005; and a third
interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
4,585,770, is granted for an additional
period of one year from the extended
expiration date of the patent, i.e., until
October 12, 2006.
Dated: March 29, 2006.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. E6–4831 Filed 4–3–06; 8:45 am]
BILLING CODE 3510–16–P
E:\FR\FM\04APN1.SGM
04APN1
]]>Agencies
[Federal Register Volume 71, Number 64 (Tuesday, April 4, 2006)]
[Notices]
[Page 16765]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-4831]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO-P-2006-0020]
Grant of Interim Extension of the Term of U.S. Patent No.
4,585,770; ZILMAX[reg] (Zilpaterol Hydrochloride)
AGENCY: United States Patent and Trademark Office, DOC.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued
certificates under 35 U.S.C. 156(d)(5) for three one-year interim
extensions of the term of U.S. Patent No. 4,585,770.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Patent Ext., P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755, or by e-mail to Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to a year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On March 26, 2003, patent owner, Hoechst Roussel Vet S.A., timely
filed an application under 35 U.S.C. 156(d)(5) for an interim extension
of the term of U.S. Patent No. 4,585,770. On March 31, 2004, patent
owner, Hoechst Roussel Vet S.A., timely filed a second application
under 35 U.S.C. 156(d)(5) for a second interim extension of the term of
U.S. Patent No. 4,585,770. On March 29, 2005, patent owner, Hoechst
Roussel Vet S.A., timely filed a third application under 35 U.S.C.
156(d)(5) for a third interim extension of the term of U.S. Patent No.
4,585,770. The patent claims the active ingredient, zilpaterol
hydrochloride, in the animal drug product Zilmax[reg]. The application
indicates that an Investigational New Animal Drug Application for the
animal drug product, Zilmax[reg] (zilpaterol hydrochloride), has been
filed and is currently undergoing regulatory review before the Food and
Drug Administration for permission to market or use the product
commercially.
Review of the application indicates that, except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for one year as required by 35
U.S.C. 156(d)(5)(B). Since it is apparent that the regulatory review
period has continued beyond the original expiration date of the patent
(October 12, 2003), interim extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 4,585,770, is granted for a period of one year from the
original expiration date of the patent, i.e., until October 12, 2004; a
second interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 4,585,770, is granted for an additional period of one year
from the extended expiration date of the patent, i.e., until October
12, 2005; and a third interim extension under 35 U.S.C. 156(d)(5) of
the term of U.S. Patent No. 4,585,770, is granted for an additional
period of one year from the extended expiration date of the patent,
i.e., until October 12, 2006.
Dated: March 29, 2006.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual Property and Director of
the United States Patent and Trademark Office.
[FR Doc. E6-4831 Filed 4-3-06; 8:45 am]
BILLING CODE 3510-16-P
